

# Schedule

Time	Talk	Session & Speaker
09:30 – 10:00	Registration & Breakfast	
10:00 – 10:10	Welcome	
10:10 – 10:50	Keynote Speech 1	<p>Gregory Winter (Molecular Biologist and Nobel Laureate in Chemistry in 2018)</p> <p><i>“Harnessing evolution: the development of antibodies and antibody mimics as pharmaceutical drugs”</i></p>
10:50 – 11:00	Q&A	
11:00 – 11:20	Break – Tea & coffee	
11:20 – 12:20	Panel I – Spinning Research into Action	<p>Guest Host: Jason Mellad (CEO and Co-Founder of Start Codon)</p> <p>Panelists:</p> <ol style="list-style-type: none"> <li>1. Ola Wlodek (CEO of Constructive Bio)</li> <li>2. Simon Bruner (Senior Associate at Flagship Pioneering and Co-Founder of Quotient Therapeutics)</li> <li>3. Allan Bradley (CEO of T-Therapeutics)</li> </ol>
12:20 – 13:30	Buffet Lunch	Networking opportunity with <b>all speakers</b>
13:30 – 13:40	Welcome back	
13:40 – 14:10	Keynote Speech 2	<p>Tara Donnelly (Founder of Digital Care and former Chief Digital Officer at NHS England)</p> <p><i>“No Place Like Home: Digital home care &amp; its potential to transform the NHS”</i></p>
14:10 – 14:20	Q&A	
14:20 – 15:20	Panel II – The Future is Digital and Smart	<p>Panelists:</p> <ol style="list-style-type: none"> <li>1. Reema Patel (Research Director and Head of Deliberative Engagement at Ipsos)</li> <li>2. Laksh Aithani – (Co-Founder and CEO of CHARM Therapeutics)</li> </ol>

		<ul style="list-style-type: none"> <li>3. Richard Dobson (Professor of Medical Informatics at King's College London &amp; UCL; Co-Founder CogStack)</li> <li>4. Tara Donnelly (discussion only)</li> </ul>
15:20 – 15:30	Closing Remarks	

## Speakers Bio

### **Gregory Winter (Professor in Molecular Biology, Nobel Laureate in Chemistry in 2018)**

Sir Gregory Winter was Master (2012-19), Fellow (1976-80; 1991-present) and an undergraduate (1970-73) of Trinity College Cambridge. He is a scientist, inventor and entrepreneur and best known for his research and inventions relating to therapeutic antibodies made at the Medical Research Council's Laboratory of Molecular Biology in Cambridge. He founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009, and shared the Nobel Prize in Chemistry in 2018.

### **Tara Donnelly (Founder of Digital Care and former Chief Digital Officer at NHS England)**

Tara Donnelly runs Digital Care, a boutique advisory firm that supports clients in the NHS and digital health innovators scale digital care, with a particular emphasis on digital home care.

Tara has worked in the NHS for 30 years, with a career that has spanned a range of operational roles in hospitals across London including Director of Operations at the Whittington, Managing Director roles at University College London Hospitals and Chief Executive of the West Middlesex University Hospital. Her second Chief Executive position was leading the Health Innovation Network, the academic health science network for south London. Most recently she was the Chief Digital Officer for NHS England.

She is Trustee and Senior Independent Director of leading think tank, the Nuffield Trust and President of the Health CEOs' Club. Her prior Trustee experience includes ten

years on the Board of Macmillan Cancer Support. Tara publishes regular articles on digital home care in a range of settings and these are collated on her website <https://digital.care/>

### **Jason Mellad (CEO and Co-Founder of Start Codon)**

Jason is a scientist and entrepreneur, passionate about translating innovative technologies into better patient outcomes.

As CEO and Co-Founder of Start Codon, a UK-based accelerator, he aims to discover the most disruptive life science, BioTech and healthcare founders and help them translate their innovations into successful ventures. This is achieved through a combination of seed funding and a bespoke venture-building programme, which taps into the exceptional resources of the Cambridge cluster as well as the global network and knowledge of Jason and the Start Codon team.

Previously, he was CEO of Cambridge Epigenetix (now Biomodal) and Business Development Manager for Horizon Discovery's diagnostics division. He also served as an associate for Cambridge Enterprise, the technology transfer office of the University of Cambridge.

Originally from Louisiana, Jason was awarded a Marshall Scholarship to complete his PhD in Medicine at the University of Cambridge (Clare College) after graduating Summa Cum Laude from Tulane University with a BSc in Molecular Biology and Chemistry. He is also a visiting Fellow at Jesus College, Cambridge, and lives in Cambridge with his husband and sons.

### **Allan Bradley (CEO of T-Therapeutics)**

Allan is the CEO of T-Therapeutics and a world-renowned researcher and entrepreneur. He is a Fellow of the Royal Society and Academy of Medical Sciences. He was Director of the Wellcome Trust Sanger Institute for 10 years from and was responsible for transitioning its high-throughput genome-sequencing infrastructure into a highly productive academic genome centre.

Allan's academic research formed the foundation in 2010 of the humanised antibody discovery company, Kymab Ltd which has resulted in the discovery of a number of novel antibodies that have demonstrated benefit in clinical trials. In January 2021, it was announced that Sanofi had acquired Kymab for \$1.45 billion. This ground-breaking

platform was conceived at the Sanger Institute and developed through 10 years within Kymab. This technology subsequently formed the basis of the animal health company PetMedix that Allan founded in 2018 and was acquired by the leading animal health company, Zoetis in 2023.

In his academic role, Allan's laboratory has authored more than 300 primary research articles, with many published in high impact journals. He is a respected expert in the monoclonal antibody and mouse engineering fields. Previously he was a Howard Hughes Medical Institute Investigator at Baylor College of Medicine (Houston, USA) where he built up one of the biggest transgenic mouse activities in the USA and also spun-out Lexicon Genetics, another successful pharmaceutical company based on mouse genetic technology. Lexicon's \$1bn debut on the NASDAQ was achieved 5 years after it was founded.

### **Ola Wlodek (CEO of Constructive Bio)**

Ola is the CEO of Constructive Bio. She holds a PhD in Biological Sciences from the University of Cambridge and executive MBA from Warwick Business School. Her scientific interests in genetic engineering of GC-rich microbes, unnatural products and peptide cyclisation led her to seek transformative applications of synthetic biology in the real world. Prior to joining Constructive Bio, she worked for various companies in the Cambridge biotech cluster, most recently as Chief Operating Officer at Reflection Therapeutics.

### **Simon Brunner (Senior Associate at Flagship Pioneering and Co-Founder of Quotient Therapeutics)**

Simon Brunner is a Senior Associate at Flagship Pioneering, where he works as part of a venture-creation team to found and grow companies based on new biotechnology.

Before joining Flagship, Simon co-founded a cancer diagnostics startup that focused on using whole-genome sequencing and data science to radically improve the lives of patients through personalised treatment selection. Prior to that, Simon was a lead data scientist and project leader at the Boston Consulting Group, advising biopharma and health insurance clients.

Simon holds a PhD in Biology from the University of Cambridge and a BS and MS in Systems Biology from ETH Zurich. After his PhD, Simon completed a postdoctoral fellowship at the Wellcome Sanger Institute, working with Peter Campbell to pioneer new approaches to study the somatic genomes of diseased tissue.

## **Laksh Aithani (Co-Founder and CEO of CHARM Therapeutics)**

Laksh is a scientist and entrepreneur, who founded CHARM Therapeutics in 2021 with David Baker. CHARM is an AI drug discovery company working on small molecules targeting drivers of cancer. They have raised over \$70m in equity funding from leading investors such as OrbiMed, F-Prime, General Catalyst, Khosla Ventures, BMS and NVIDIA.

Prior to founding CHARM, he was a core contributor at Exscientia (NASDAQ:EXAI), a leading AI drug discovery company, where he worked on their machine learning platform.

Laksh started his entrepreneurship journey during University, co-founding Genei, an AI company, which has since gone through Y-Combinator and raised a seed round from Silicon Valley investors.

Laksh gained his degree in Natural Sciences from the University of Cambridge, with a Double First Class.

## **Reema Patel (Research Director and Head of Deliberative Engagement at Ipsos)**

Reema Patel is a thought-leader in the fields of technology, data and AI ethics, public engagement and participation, and diversity, equity and inclusion. She presently leads global research agency Ipsos's work on deliberative engagement. She co-founded the Ada Lovelace Institute where she established its work on public engagement and participation. She is an author of several Ada Lovelace Institute's reports, including Beyond Face Value, Rethinking Data, The Data Divide and Participatory Data Stewardship among others. She also co-authored a report for On Think Tanks on the global evidence base for public engagement.

Before working at the Ada Lovelace Institute, Reema advised the Bank of England on their approach to public engagement and participation in economics, work that was

endorsed by the Bank's Chief Economist in an official speech entitled Climbing the Public Engagement Ladder. She continues to serve as a member of the Bank of England's Central Bank Digital Currency Engagement Forum, and is a Senior Fellow of the Finance Innovation Lab.

### **Richard Dobson (Head of Dept of Biostatistics and Health Informatics at King's College London, Co-Founder of CogStack Ltd)**

Richard is Professor of Health Informatics, Head of Dept of Biostatistics and Health Informatics at King's College London, is also based at University College London and is Co-Founder of CogStack Ltd (CogStack.org), a clinical language AI NHS/academic spinout.

He has over 15 years experience in developing data & AI with the NHS. International Leadership roles including the OLS Mental Health Mission; major Horizon-2020 industry-academic programmes, NIHR programmes and HDR UK programmes. He has numerous advisory roles for UK national strategy, policy and UKRI funding and also co-directs a Centre for Doctoral Training in Data Driven Health (DRIVE-Health.org.uk) with major industry, NHS, academic and 3rd sector partnerships.

He has >450 peer-reviewed papers on healthcare informatics, natural language processing/LLMs and wearable technologies